Piramal Pharma targets $2 bn revenue by FY30
Business Standard|September 26, 2024
Pharmaceutical firm Piramal Pharma is eyeing to double its revenue to $2 billion by 2029-30, company Chairperson Nandini Piramal said on Wednesday.
- SOHINI DAS
Piramal Pharma targets $2 bn revenue by FY30

At the same time, the earnings before interest, depreciation, and amortisation (Ebitda) would triple and the company aims to bring down its net debt to Ebitda levels to 1x by FY30 from the current 2.9x.

この蚘事は Business Standard の September 26, 2024 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

この蚘事は Business Standard の September 26, 2024 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

BUSINESS STANDARDのその他の蚘事すべお衚瀺
Refurbished premium phones a favourite this festival season
Business Standard

Refurbished premium phones a favourite this festival season

iPhones, Samsung drive demand in recommerce space

time-read
3 分  |
September 27, 2024
US tariffs risk Chinese goods flooding India
Business Standard

US tariffs risk Chinese goods flooding India

Tariffs up to 100% on key items from China take effect today

time-read
3 分  |
September 27, 2024
Business Standard

Promoter dilution in small, midcaps surges

The controlling shareholders of smaller and mid-sized companies are reducing their stakes at levels seldom seen since the 2008 global financial crisis.

time-read
2 分  |
September 27, 2024
Business Standard

Pickup in public expenditure may keep growth steady: FinMin

After witnessing contraction in the first quarter of the current financial year (Q1FY25), the government is expecting public expenditure to pick up in the remaining quarters, even though there is a need for monitoring automobiles and fast moving consumer goods (FMCG) sales due to slowdown seen in Q1, the finance ministry (FinMin)'s Monthly Economic Review for August said. After witnessing contraction in the first quarter of the current financial year (Q1FY25), the government is expecting public expenditure to pick up in the remaining quarters, even though there is a need for monitoring automobiles and fast moving consumer goods (FMCG) sales due to slowdown seen in Q1, the finance ministry (FinMin)'s Monthly Economic Review for August said.

time-read
1 min  |
September 27, 2024
Business Standard

BFSI sector valuation discount at new high

Valuation re-rating has been much sharper for non-BFSI companies

time-read
3 分  |
September 27, 2024
Top 5 pvt equity players invested $9 bn in H1CY24
Business Standard

Top 5 pvt equity players invested $9 bn in H1CY24

The funding environment in India for startups is improving this year if one were to go by Bain & Company estimates.

time-read
2 分  |
September 27, 2024
No plans to list diagnostic arm: IHH Healthcare CEO
Business Standard

No plans to list diagnostic arm: IHH Healthcare CEO

Malaysia's IHH Healthcare, which operates hospital networks under Fortis and Gleneagles brands, has no plans to list its diagnostics arm Agilus Diagnostics, a Fortis subsidiary, senior company officials said.

time-read
1 min  |
September 27, 2024
Greenfield hotel investments return to pre-pandemic levels in H1
Business Standard

Greenfield hotel investments return to pre-pandemic levels in H1

Surge fuelled by expansion in Tier-II, -III, -IV cities

time-read
2 分  |
September 27, 2024
Business Standard

‘Focus on increasing visibility in top-tier locations’

Costa Coffee, which has a store count of 200 across the country, continues to expand at a steady pace in the Indian market. In an exclusive interview, VINAY NAIR, vice-president, Costa Coffee, India and emerging markets, spoke in a video interview with Sharleen D'Souza on the healthy growth that the coffee market is witnessing in India. Edited excerpts:

time-read
2 分  |
September 27, 2024
Business Standard

Singapore court grants WazirX four-month moratorium

A Singapore court on Thursday granted a four-month moratorium to Indian cryptocurrency exchange WazirX, a period which the embattled firm will use to restructure its business without worrying about legal proceedings.

time-read
1 min  |
September 27, 2024